CPG
FENC icon

Cornerstone Planning Group’s Fennec Pharmaceuticals FENC Stock Holding History

Cornerstone Planning Group’s Portfolio FENC Stock Details FENC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$592 Hold
88
– – ﹤0.01% 1598
2025
Q4 		$656 Hold
88
– – ﹤0.01% 1457
2025
Q3 		$733 Hold
88
– – ﹤0.01% 1391
2025
Q2 		$719 Hold
88
– – ﹤0.01% 1192
2025
Q1 		$497 Hold
88
– – ﹤0.01% 1311
2024
Q4 		$576 Hold
88
– – ﹤0.01% 1093
2024
Q3 		$422 Buy
+88
New +$509 ﹤0.01% 1122
2024
Q2 		– Sell
-66
Closed -$610 – 1291
2024
Q1 		$610 Buy
+66
New +$663 ﹤0.01% 880

Other funds holding FENC

RA
Rosalind Advisors Toronto, Ontario, Canada $249M AUM 80.12% 1-Year Est. Return
SCA
Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return
SCM
Solas Capital Management Darien, Connecticut $174M AUM 6.33% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCM
Potomac Capital Management New York $115M AUM

Cornerstone Planning Group's FENC Position: Q1 2026 in Review

Cornerstone Planning Group held its Fennec Pharmaceuticals (FENC) position steady in Q1 2026 at 88 shares worth $592. The position accounts for ﹤0.01% of the portfolio, ranked #1598.

Cornerstone Planning Group first reported a position in FENC in Q1 2024 and has held it in 8 quarters since. The position peaked at $733 in Q3 2025. 90 funds tracked by Wall St. Rank hold FENC as of Q1 2026.

  • Cornerstone Planning Group held 88 shares of Fennec Pharmaceuticals worth $592 as of Q1 2026.
  • Cornerstone Planning Group left its Fennec Pharmaceuticals share count unchanged in Q1 2026.
  • Fennec Pharmaceuticals made up ﹤0.01% of Cornerstone Planning Group's portfolio in Q1 2026, its #1598 holding.
  • Cornerstone Planning Group first reported a position in Fennec Pharmaceuticals in Q1 2024 and has held it in 8 quarters since.
  • Cornerstone Planning Group's Fennec Pharmaceuticals position peaked at $733 in Q3 2025.
  • 90 funds tracked by Wall St. Rank held Fennec Pharmaceuticals as of Q1 2026.

Based on Cornerstone Planning Group's 13F filing for Q1 2026, filed 6 May 2026.